Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yen-Yang Chen

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
BMC Cancer|March 1, 2018
Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinomaMing-Chun Ma, Yi-Ju Chen, Tai-Jan Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of ImatinibChien-Feng Li, Fu-Min Fang, Yen-Yang Chen, et al.
Journal of Clinical Medicine|November 4, 2018
Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal TumorsChien-Feng Li, Ting-Ting Liu, Jui-Chu Wang, et al.
Oncology Reports|July 18, 2018
MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patientsChi-Tung Cheng, Yen-Yang Chen, Ren-Chin Wu, et al.
Oncotarget|May 11, 2017
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, et al.
Cancers|August 27, 2020
S1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection-A Propensity Score Matching AnalysisMeng-Che Hsieh, Shih-Ho Wang, Ching-Ting Wei, et al.
Oncotarget|February 18, 2017
PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survivalChien-Feng Li, Ting-Ting Liu, I-Chieh Chuang, et al.
Cancers|January 13, 2019
Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic ModelChing-Fu Chang, Pei-Wei Huang, Jen-Shi Chen, et al.
Experimental and Therapeutic Medicine|November 10, 2012
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancersKun-Ming Rau, Chao-Cheng Huang, Tai-Jan Chiu, et al.
Radiology and Oncology|September 2, 2014
Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasisYu-Li Su, Shan-Hsuan Li, Yen-Yang Chen, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
BMC Cancer|March 1, 2018
Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinomaMing-Chun Ma, Yi-Ju Chen, Tai-Jan Chiu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of ImatinibChien-Feng Li, Fu-Min Fang, Yen-Yang Chen, et al.
Journal of Clinical Medicine|November 4, 2018
Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal TumorsChien-Feng Li, Ting-Ting Liu, Jui-Chu Wang, et al.
Oncology Reports|July 18, 2018
MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patientsChi-Tung Cheng, Yen-Yang Chen, Ren-Chin Wu, et al.
Oncotarget|May 11, 2017
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, et al.
Cancers|August 27, 2020
S1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection-A Propensity Score Matching AnalysisMeng-Che Hsieh, Shih-Ho Wang, Ching-Ting Wei, et al.
Oncotarget|February 18, 2017
PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survivalChien-Feng Li, Ting-Ting Liu, I-Chieh Chuang, et al.
Cancers|January 13, 2019
Prognostic Factors for Advanced Pancreatic Cancer Treated with Gemcitabine Plus S-1: Retrospective Analysis and Development of a Prognostic ModelChing-Fu Chang, Pei-Wei Huang, Jen-Shi Chen, et al.
Experimental and Therapeutic Medicine|November 10, 2012
Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancersKun-Ming Rau, Chao-Cheng Huang, Tai-Jan Chiu, et al.
Radiology and Oncology|September 2, 2014
Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasisYu-Li Su, Shan-Hsuan Li, Yen-Yang Chen, et al.
Pageof 10